Status:
COMPLETED
An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone
Lead Sponsor:
Janssen Cilag N.V./S.A.
Conditions:
Schizophrenia
Eligibility:
All Genders
Brief Summary
The purpose of this study is to assess treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone.
Detailed Description
This is an observational (study in which patients/participants are observed) and multicentre (at multiple sites) study. This is one-country arm of a multinational study. This study consists of 2 years...
Eligibility Criteria
Inclusion
- Patient who started long-acting injectable risperidone treatment after agreement between doctor and patient
- Ambulatory patient or not chronically full-time hospitalized patient. Full-time hospitalization at the moment of inclusion for maximal 6 months
- The treatment and treated indication according to local label
- Patient had given informed consent in agreement with local legislation
Exclusion
- Patient participating in another medication related study, chronically full-time hospitalized patient, who according to the treating physician had no perspective of being discharged within the planned observation period
- Patient suffering from treatment resistant schizophrenia
- Pregnant or breastfeeding females or females with planned pregnancy within two years
Key Trial Info
Start Date :
November 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
408 Patients enrolled
Trial Details
Trial ID
NCT00774085
Start Date
November 1 2004
End Date
December 1 2007
Last Update
April 27 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.